Adult Canine

Giant breed dogs: 1-5 years of age
Large breed dogs: 1-7 years of age
Small breed dogs: 1-10 years of age

Vaccines & Schedules

Vaccine

Booster Recommendation

Comments

CORE VACCINES

Every 1 or 3 years

Follow local regulations.

After 1-yr and then every 3-yr

Included in DAPPV/3-yr DAPV

Parvovirus*

After 1-yr and then every 3-yr

Included in DAPPV/3-yr DAPV

Adenovirus type 1 

(CAV-1, canine hepatitis)*

After 1-yr and then every 3-yr

Included in DAPPV/3-yr DAPV

ADDITIONAL VACCINES

Annual

Annual mucosal vaccination recommended for at-risk dogs (see comments below)

Annually

Recommended for at-risk dogs

Annual

Only in high-risk areas

Annually

Because all dogs are at risk due to predation or exposure to environmental contamination, vaccine is recommended for all

Canine influenza (H3N2/H3N8)

Annual

Lifestyle vaccine (exposure to otherdogs)

*Repeat once 3-4 weeks after initial vaccine if not appropriately boosted as puppy

Annual Wellness Visit Summary

Service Provided

Product / Service Info

Medical Services

Physical Examination

Nail Trim

Maintenance

Anal Sac Expression

Maintenance

Immunization

Rabies 3-years vaccine

VANGUARD RABIES 3 YEAR (Zoetis)

NOBIVAC 3-RABIES (Merck)

IMRAB 3 TF (BI)

RAB VAC 3 (Elanco)

DAPV 3-years vaccine

NOBIVAC CANINE 3-DAPV (Merck)

Bordetella/Parainfluenza combo vaccine

NOBIVAC Intra-Trac Oral BbPi (Merck)

Leptospirosis vaccine

LEPTOVAX 4 (Elanco)

RECOMBITEK 4 LEPTO (BI)

NOBIVAC LEPTO4 (Merck)

VANGUARD L4 LEPTO (Zoetis)

Bivalent Influenza Vaccine

VANGUARD CIV H3N2 H3N8 (Zoetis)

Lyme Vaccine

NOBIVAC LYME (Merck)
DURAMUNE LYME VACCINE (Elanco)
RECOMBITEK LYME (BI)

Diagnostics

Adult Annual with Fecal Dx® Profile andLab 4Dx® Plus Test (38749999)

Chem 18 with IDEXX SDMA® Test, IDEXX CBC®,fecal ova and parasites, hookworm, roundworm and whipworm antigen immunoassays, Lab4Dx® Plus Test

AFAST/TFAST Wellness Ultrasound scan(Package Deal)

*Ultrasound-guided cystocentesis also performed during routine AFAST for routine urinalysis included in IDEXX profile

Preventatives

Interceptor plus

1 dose administered/provided

Simparica Trio Chewable Tablets

6 month supply provided

Dental Chews

CET Chews

Immunization

  • Rabies and DAPV 3-years vaccines ensure long term protection from 4 pathogens represented in core vaccines.
  • Merck’s NOBIVAC CANINE 3-DAPV vaccine prevents infections caused by CAV-1 and infections associated with CAV-2 (see explanation below), as well as Distemper and Parvovirus [1].
  • The only gap in protective immunity remaining by switching from DA2PP every three years can create a lapse in immunity to parainfluenza virus, which requires annual boostering for an optimal immune response. This can be overcome by vaccinating at-risk dogs annually with a combination mucosal Bordetella and parainfluenza vaccine, either oral or intranasal.
  • Merck’s NOBIVAC Intra-Trac Oral BbPi combo vaccine:
    —Provides protective immunity and systemic immunity from both parainfluenza and bordetella, 2 of the most common respiratory pathogens.

    —Immuno-Mist-RTM oral spray applicator exposes immune cells to antigen.
  • Canine adenoviruses [2]
    —CAV-1 and CAV-2 cause infectious canine hepatitis (ICH) and canine infectiouS respiratory tract disease (CIRDC), respectively.

    —Because vaccination with CAV-1 strains has been associated with corneal edema, and vaccination with CAV-2 provides cross-protection against CAV-1 infection, CAV-2 is used in DAP vaccines to prevent ICH. It may also provide some protection against CAV-2 infection.
  • Bordetella vaccines:
    —Intranasal vaccines are available to reduce disease caused by Bordetella, parainfluenza and canine adenovirus-2. Oral vaccines are available to reduce disease caused by Bordetella or Bordetella/parainfluenza.

    —Mucosal vaccines provide more rapid onset of action when compared with parenteral vaccines and may provide an improved mucosal immune response.

    —We do not recommend using the monovalent oral Bordetella vaccine. This includes-—VANGUARD® B ORAL (Zoetis)
    Intra-Trac® Oral Bb (Merck)
    Recombitek Oral Bordetella (BI)

Other available vaccines: 

VACCINE

PRODUCT INFO

Rabies 1-year vaccine

IMRAB 1 (BI)
RABVAC 1 RABIES VACCINE (Elanco)
NOBIVAC RABIES 1 (Merck)
VANGUARD RABIES 1 (Zoetis)

DA2PP + Leptospirosis vaccine combo

ULTRA DURAMUNE DAP PLUS 4L (Elanco; SQ)
VANGUARD DAPP/L4 (Zoetis; SQ)
NOBIVAC CANINE 1-DAPPV PLUS L4 (Merck; SQ)

Bordetella

Tier 1: Intranasal

VANGUARD® RAPID RESP 3 (Zoetis)
NOBIVAC INTRA-TRAC3 (Merck)
BRONCHI-SHIELD III (Elanco)
Recombitek KC2 Vaccine (BI)

Tier 2: Parenteral

VANGUARD® B INJECTABLE (Zoetis)

Diagnostics

HealthChek™ with Fecal Dx® Profile, Lab 4Dx® Plus and Urinalysis (89369999) covers the necessary elements for early detection and prevention of common diseases, and thus the recommended test by The Vets Internal Medicine expert, Dr. Andrea Johnston. Possible alternatives are outlined below.

Test Name

Info

Price

TIER 1

HealthChek™ with Fecal Dx®Profile, Lab 4Dx® Plus and Urinalysis (89369999)

Chem 25 with IDEXX SDMA® Test, IDEXXCBC™, fecal ova and parasites,hookworm, roundworm, whipwormantigen immunoassays, Lab 4Dx® PlusTest, urinalysis

$336.90

TIER 2

Adult Annual with Fecal Dx® Profileand Lab 4Dx® Plus Test (38749999)

Chem 18 with IDEXX SDMA® Test, IDEXXCBC®, fecal ova and parasites, hookworm, roundworm and whipworm antigen immunoassays, Lab 4Dx® Plus Test

$199

TIER 3

Adult Wellness (12729999)

Chem 21 with IDEXX SDMA® Test, IDEXX CBC®

$161.18

Heartworm Test - In House

$45

Fecal Dx® Antigen Panel Add-on—Canine/Feline (51991)

$34.21

Parasiticides

  • Simparica Trio Chewable Tablets is the only broad spectrum single preventative and thus our Tier 1 recommendation. SImparica Trio provides protection from fleas (kills adult fleas and the eggs after they hatch), ticks, heartworm, hookworms and roundworms.
  • In case of known sensitivity to Simparica Trio, the recommended alternative is a combination of Interceptor Plus and Credelio or Bravecto. This combination provide protection from fleas, ticks, heartworm, hookworms, roundworms, whipworms and tapeworms.
  • Bravecto kills adult fleas and the eggs after they hatch, and has a protection duration of 3 months. Credelio only kills adult fleas and has has a protection duration of 1 month.
  • For pets previously positive for whipworm, the combination of Interceptor Plus and Credelio or Bravecto should be recommended. This is due to it’s high pathogenecity and ability to stay in the ground for a long period of time.

Parasiticides Comparison

Companion Animal Parasite Council (CAPC) Data

Discussion Points for Pet Parents

ASPCA Animal Poison Control

https://www.aspca.org/pet-care/animal-poison-control

  • If you think your pet may have ingested a potentially poisonous substance, call (888) 426-4435.
  • List of toxic plants with images. Most dangerous toxic plants: Sago palms, azaleas, and rhododendrons.
  • List of toxic human foods. Most dangerous human foods: chocolate, grapes, raisins, onions, garlic, chives, and products containing xylitol sweetener.

Raw food diets

The AVMA and AAHA discourage the feeding of raw animal-source protein to dogs due to the high risk of illness to both pets and humans. Pathogens found in raw protein diets can be transmitted to the human population by contact with the food, pet, or environmental surfaces.

Neutering / Spaying

Neutering is associated with a prolonged life expectancy for both sexes compared to their entire counter parts. This has been reported in multiple studies. In female dogs, neutering reduces or eliminates the risk of pyometra, a potentially life-threatening condition. Neutering is linked to a reduced risk of cancer of reproductive organs and heart disease, but an increased risk of joint disorders and some cancers (lymphoma and hemangiosarcoma) especially in females. [1,2]

Breed Associated Health Risks (3-6)

Health risks by breed can be found at https://www.akc.org/ under the Health link on each breedinformation page. A handful of large scale publications on breed related mortality are available.


Brachycephalic (short nosed) breeds

Brachycephalic breeds (French Bulldog, English Bulldog, Pug, and American Bulldog) are predispositions to life-limiting disorders that occur early in life, such as brachycephalic obstructive airway syndrome (BUAS), spinal disease, and dystocia.Brachycephalic breeds should avoid high temperatures, overexertion, and over-conditioning(obesity). Harnesses rather than collars should be used for leash walks. Preemptive surgical intervention to improve upper airway conformation should be recommended before a respiratory crisis occurs.

Deep chested, large and giant breed dogs

Deep chested, large breed dogs (Great Danes, Weimaraners, St. Bernards, Irish setters, Gordonsetters…) are predisposed to gastric dilation and volvulus (GDV). Pre-emptive gastropexy should be recommended to reduce the risk of GDV. Feed more than one meal a day and select a dog food with a low fat and oil content.

Chondrodystrophic breeds

Chondrodystrophic breeds (Dachshund, Pekinese, Beagle, Lhasa Apso) are predisposed to intervertebral disk disease (IVDD). Avoid over-feeding and obesity. Use a harness rather than a collar for leash walks. Avoid high impact activities like jumping on and off furniture, consider the use of portable pet stairs.

Congenital cardiovascular disease [7,8]

Many breeds are predisposed to congenital heart disease. If a murmur or arrhythmia is detected on annual physical exam, a thoracic radiograph or EKG should be pursued. If these are abnormal, a cardiology referral is recommended. [6, open access journal with helpful diagnostic flow chart]

● Aortic Stenosis: Boxers, Golden Retrievers, Rottweilers, German Shepherds, Newfoundlands

● Pulmonic Stenosis: Boston terriers, Boxers, English Bulldogs, French Bulldogs, BoykinSpaniels, Jack Russell Terriers, Keeshonds, terriers

● Patent Ductus Arteriosus (PDA): Small breed dogs, German Shepherds, Newfoundland

● Ventricular Septal Defect (VSD): English Springer Spaniels

Congenital kidney disease

● Renal dysplasia: Alaskan Malamutes, Bedlington Terriers, Chow Chows, Cocker Spaniels,Doberman Pinschers, Keeshonden, Lhasa Apsos, Miniature Schnauzers, NorwegianElkhounds, Samoyeds, Shih Tzus, Soft-coated Wheaten Terriers, and Standard Poodles

o Usually diagnosed via renal ultrasound imaging in juveniles in conjunction with azotemia, isosthenuria.

● Polycystic kidney disease: Beagles, Bull Terriers, Cairn Terriers, and West Highland White Terrier

o Diagnosis is usually made via renal ultrasound in juveniles

Congenital hepatobiliary disease including vascular anomalies

● Ductal plate malformations: Boxers

● Portosystemic vascular malformations (Extravascular portosystemic shunts): Small and Toy breeds (Bichon Frise, Border terriers, Maltese, Yorkshire terriers, Cairn terriers, Havanese, Miniature schnauzer, Silky terriers) should be screened for congenital portosystemic vascularmalformations. Large breed dogs (Labrador retrievers, Siberian Husky) occasionally haveintrahepatic portosystemic shunts.

o If a paired serum bile acids test is abnormal, submit a protein C level to CornellCoagulation Laboratory. A protein C less than 70% is consistent with a portosystemicshunt, between 70-99% is in the grey zone, and a value greater than 100% is normal, consistent with microvascular dysplasia. Dogs with a portosystemic shunt should be started on medical management (modified protein diet (Hill’s l/d or Royal Canin Hepatic, lactulose, and gut flora modulation). A CT angiogram will be needed if surgical shunt attenuation will be pursued or to definitively diagnose dogs in the gray zone. No therapy is needed for dogs with microvascular dysplasia.

Bite-Size Mucosal Immunology & Vaccination Route Information

Vaccination is an efficient and cost-effective form of infectious disease prevention. Most current vaccines are delivered by injection, which provide systemic protection but partial to no protection at mucosal sites. Considering that >90% of pathogens gain access to the body via mucosal sites, using mucosal vaccination to generate protective immunity at mucosal sites could overcome the limitations of current injection-based vaccines in providing front-line protection against pathogen invasion and dissemination (Holmgren J., Czerkinsky C., 2005; Gerdts V. et al., 2006).

Mucosal tissues (e.g. nasal, oral, ocular, rectal, vaginal) cover a large surface of the body. Since many infections are initiated at mucosal sites, it is critical to develop strategies for neutralizing the infectious agent at these surfaces. Mucosal vaccination involves the administration of vaccines at one or more mucosal sites leading to induction of immune responses at the mucosal site of administration, other mucosal sites, and/or systemically.

Immunization involves the delivery of antigens to the mucosal immune system (into

units such as Peyer’s patches in the intestine or the nasal-associated lymphoid tissue in the oropharyngeal cavity). The effector mechanisms for mucosal immune response include the hallmark secretory Immunoglobulin A (SIgA), a protease-resistant antibody and the cell-mediated mucosal immune response. These effectors have been shown to be effective for the clearance of various pathogens including enteric/respiratory viruses and intracellular parasites.

IgA is the first line of defense in the resistance against infection, via inhibiting bacterial

and viral adhesion to epithelial cells and by neutralization of bacterial toxins and virus, both extra- and intracellularly. IgA also eliminates pathogens or antigens via an IgA-mediated excretory pathway where binding to IgA is followed by polyimmunoglobulin receptor-mediated transport of immune complexes. SIgA has an important role in mediating the adaptive (antigen specific) humoral (antibody-based) immune defense at mucosal surfaces.

The majority of mucosal vaccines are administered by the oral and nasal routes.

However, not all routes of administration induce an equivalent immune response in terms of potency and longevity, reflecting differences in the organization and cellular make-up of lymphoid structures in different mucosal tissues (Kantele A., et al., 1998; Czerkinsky C., et al., 2012; Czerkinsky C., Holmgren J., 2010).

For example, oral immunization usually stimulates immune responses in the GI tract in

addition to the oral mucosa and nasal-associated lymphoid tissues (NALT) and mammary glands. Intranasal delivery effectively induces antibody production in salivary glands, the NALT and the bronchus-associated lymphoid tissue (BALT) of the lower respiratory tract, and in the urogenital tract. Rectal immunization elicits a more pronounced immune and antibody response in nasal secretions, tears and the rectal mucosa. Thus, depending on the mucosal sites targeted by different pathogens, the route of immunization needs to be carefully considered (Fujkuyama Y., et al., 2012; Czerkinsky C., Holmgren J., 2010; Saroja C., et al., 2011).

Resources

Sources

  1. Gore TC, Lakshmanan N, Duncan KL, Coyne ML, Lum MA, Sterner FJ. Three-year duration of immunity in dogs following vaccination against canine adenovirus type-1, canine parvovirus, and canine distemper virus. Vet Ther. 2005;6(1):5–14.
  2. Zhu Y, Xu J, Lian S, Zhang R, Hou J, Want M, Yan X. Difference Analysis Between Canine AdenovirusTypes 1 And 2. 2022;12: 854876.
  3. Teng K.T., Brodbelt D.C., Pegram C., Church D.B., O'Neill D.G. Life tables of annual life expectancy and mortality for companion dogs in the United Kingdom. Sci Rep. 2022 Apr 28;12(1):6415. doi:10.1038/s41598-022-10341-6. PMID: 35484374; PMCID: PMC9050668.4.
  4. Urfer, S. R. & Kaeberlein, M. Desexing dogs: A review of the current literature. Animals 9, 1086 (2019).42.
  5. Hart, L. A. & Hart, B. L. An ancient practice but a new paradigm: Personal choice for the age to spay or neuter a dog. Front. Vet. Sci. 8, 244 (2021).
  6. O’Neill, D. G., Church, D. B., McGreevy, P. D., Tomson, P. C. & Brodbelt, D. C. Longevity and mortality of owned dogs in England. Vet. J. 198, 638–643 (2013).
  7. Brambilla P.G., Polli M., Pradelli D., Papa M., Rizzi R., Bagardi M., Bussadori C. Epidemiological study ofcongenital heart diseases in dogs: Prevalence, popularity, and volatility throughout twenty years ofclinical practice. PLoS One. 2020 Jul 27;15(7):e0230160. doi: 10.1371/journal.pone.0230160. PMID:32716943; PMCID: PMC7384636.
  8. Saunders AB. Key considerations in the approach to congenital heart disease in dogs and cats. J SmallAnim Pract. 2021 Aug;62(8):613-623. doi: 10.1111/jsap.13360. Epub 2021 Jun 27. PMID: 34180062.

Ask the Board!